Global Remicade (Infliximab) Monoclonal Antibody Market Growth 2023-2029

Global Remicade (Infliximab) Monoclonal Antibody Market Growth 2023-2029

The global Remicade (Infliximab) Monoclonal Antibody market size is projected to grow from US$ 2494.5 million in 2022 to US$ 3703.9 million in 2029; it is expected to grow at a CAGR of 5.8% from 2023 to 2029.

The Remicade (Infliximab) monoclonal antibody market is driven by several factors. One of the primary drivers is the high prevalence of chronic autoimmune diseases, such as rheumatoid arthritis, Crohn's disease, and psoriasis, which require targeted immunotherapy for effective management. Remicade, as a monoclonal antibody, has demonstrated significant efficacy in treating these conditions by specifically targeting and inhibiting tumor necrosis factor-alpha (TNF-alpha), a key mediator of inflammation. Additionally, the increasing adoption of biologic therapies, including monoclonal antibodies, in clinical practice has fueled the demand for Remicade. The proven clinical efficacy, long-term safety profile, and established therapeutic outcomes have contributed to its market growth. Moreover, the expanding patient pool, coupled with the rising awareness and diagnosis rates of autoimmune diseases, has created a greater demand for targeted biologic treatments like Remicade. Furthermore, the presence of robust research and development activities aimed at developing novel monoclonal antibodies and exploring new indications for Remicade continues to drive market growth. Overall, the Remicade monoclonal antibody market is driven by the high prevalence of autoimmune diseases, increasing adoption of biologic therapies, established clinical efficacy, expanding patient pool, and ongoing research and development efforts.

Infliximab is a monoclonal anti tumor necrosis factor alpha antibody used in the treatment of a wide variety of inflammatory conditions such as rheumatoid arthritis, Crohn's disease, and ankylosing spondylitis. Avsola, Flixabi, Inflectra, Remicade, Renflexis.

LPI (LP Information)' newest research report, the “Remicade (Infliximab) Monoclonal Antibody Industry Forecast” looks at past sales and reviews total world Remicade (Infliximab) Monoclonal Antibody sales in 2022, providing a comprehensive analysis by region and market sector of projected Remicade (Infliximab) Monoclonal Antibody sales for 2023 through 2029. With Remicade (Infliximab) Monoclonal Antibody sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Remicade (Infliximab) Monoclonal Antibody industry.

This Insight Report provides a comprehensive analysis of the global Remicade (Infliximab) Monoclonal Antibody landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Remicade (Infliximab) Monoclonal Antibody portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Remicade (Infliximab) Monoclonal Antibody market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Remicade (Infliximab) Monoclonal Antibody and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Remicade (Infliximab) Monoclonal Antibody.

This report presents a comprehensive overview, market shares, and growth opportunities of Remicade (Infliximab) Monoclonal Antibody market by product type, application, key manufacturers and key regions and countries.

Market Segmentation:

Segmentation by type
Brand
Biosimilar

Segmentation by application
Ankylosing Spondylitis
Rheumatoid Arthritis
Crohn’s Disease
Other

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
J & J
Pfizer
Organon
Amgen

Key Questions Addressed in this Report

What is the 10-year outlook for the global Remicade (Infliximab) Monoclonal Antibody market?

What factors are driving Remicade (Infliximab) Monoclonal Antibody market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Remicade (Infliximab) Monoclonal Antibody market opportunities vary by end market size?

How does Remicade (Infliximab) Monoclonal Antibody break out type, application?

What are the influences of COVID-19 and Russia-Ukraine war?

Please note: The report will take approximately 2 business days to prepare and deliver.